Pharmacological Treatment Options for Autism Spectrum Disorders in Children and Adolescents

REFERENCES

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. APA, Washington, DC 2000
   Google Scholar
• Aman M G. Treatment planning for patients with autism spectrum disorders. J Clin Psychiatry 2005; 66(suppl 10)38–45
   PubMedGoogle Scholar
• Volkmar F, Cook E H, Jr, Pomeroy J, Realmuto G, Tanguay P. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 1999; 38(suppl 12)32S–54S
   Web of Science ®Google Scholar
• Posey D J, McDougle C J. Pharmacotherapeutic management of autism. Expert Opin Pharmacother 2001; 2: 587–600
   PubMedGoogle Scholar
• Aman M G, Langworthy K S. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord 2000; 30: 451–9
   PubMed Web of Science ®Google Scholar
• King B H, Bostic J Q. An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2006; 15: 161–75
   PubMed Web of Science ®Google Scholar
• Aman M G, Lam K S, Van Bourgondien M E. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 2005; 15: 116–26
   PubMed Web of Science ®Google Scholar
• DiMartino A, Melis G, Cianchetti C, Zuddas A. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol 2004; 14: 207–18
   PubMed Web of Science ®Google Scholar
• Handen B L, Johnson C R, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000; 30: 245–55
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62: 1266–74
   PubMed Web of Science ®Google Scholar
• Greenhill L L, Pliszka S, Dulcan M K, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41(suppl 2)26S–49S
   PubMed Web of Science ®Google Scholar
• Volkmar F R, Cohen D J, Hoshino Y, Rende R D, Paul R. Phenomenology and classification of the childhood psychoses. Psychol Med 1988; 18: 191–201
   PubMed Web of Science ®Google Scholar
• Campbell M, Fish B, David R, Shapiro T, Collins P, Koh C. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Child Schizophr 1972; 2: 343–58
   PubMedGoogle Scholar
• Campbell M, Small A M, Collins P J, Friedman E, David R, Genieser N. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Ther Res Clin Exp 1976; 19: 70–86
   PubMed Web of Science ®Google Scholar
• Arnold L E, Aman M G, Cook A M, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006; 45: 1196–205
   PubMed Web of Science ®Google Scholar
• Jou R J, Handen B L, Hardan A Y. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15: 325–30
   PubMed Web of Science ®Google Scholar
• Troost P W, Steenhuis M P, Tuynman-Qua H G, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006; 16: 611–9
   PubMed Web of Science ®Google Scholar
• Posey D J, Wiegand R E, Wilkerson J, Maynard M, Stigler K A, McDougle C J. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16: 599–610
   PubMed Web of Science ®Google Scholar
• Krakowski A J. Amitriptyline in treatment of hyperkinetic children. A double-blind study. Psychosomatics 1965; 6: 355–60
   PubMed Web of Science ®Google Scholar
• Donnelly M, Zametkin A J, Rapoport J L, et al. Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther 1986; 39: 72–81
   PubMed Web of Science ®Google Scholar
• Biederman J, Baldessarini R J, Wright V, Knee D, Harmatz J S. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 1989; 28: 777–84
   PubMed Web of Science ®Google Scholar
• Gordon C T, Rapoport J L, Hamburger S D, State R C, Mannheim G B. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry 1992; 149: 363–6
   PubMed Web of Science ®Google Scholar
• Gordon C T, State R C, Nelson J E, Hamburger S D, Rapoport J L. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50: 441–7
   PubMed Web of Science ®Google Scholar
• Gualtieri C T, Evans R W. Motor performance in hyperactive children treated with imipramine. Percept Mot Skills 1988; 66: 763–9
   PubMed Web of Science ®Google Scholar
• Campbell M, Fish B, Shapiro T, Floyd A, Jr. Imipramine in preschool autistic and schizophrenic children. J Autism Child Schizophr 1971; 1: 267–82
   PubMedGoogle Scholar
• Prince J B, Wilens T E, Biederman J, et al. A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2000; 10: 193–204
   PubMed Web of Science ®Google Scholar
• Wilens T E, Biederman J, Geist D E, Steingard R, Spencer T. Nortriptyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 1993; 32: 343–9
   PubMed Web of Science ®Google Scholar
• Kurtis L B. Clinical study of the response to nortriptyline on autistic children. Int J Neuropsychiatry 1966; 2: 298–301
   PubMedGoogle Scholar
• Carminati G G, Deriaz N, Bertschy G. Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 312–5
   PubMed Web of Science ®Google Scholar
• Hollander E, Kaplan A, Cartwright C, Reichman D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol 2000; 15: 132–5
   PubMed Web of Science ®Google Scholar
• Findling R L, Schwartz M A, Flannery D J, Manos M J. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996; 57: 184–9
   PubMed Web of Science ®Google Scholar
• Olvera R L, Pliszka S R, Luh J, Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 1996; 6: 241–50
   PubMed Web of Science ®Google Scholar
• Findling R L, Greenhill L L, McNamara N K, et al. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007; 17: 433–45
   PubMed Web of Science ®Google Scholar
• Conners C K, Casat C D, Gualtieri C T, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996; 35: 1314–21
   PubMed Web of Science ®Google Scholar
• Simeon J G, Ferguson H B, Van Wyck Fleet J. Bupropion effects in attention deficit and conduct disorders. Can J Psychiatry 1986; 31: 581–5
   PubMed Web of Science ®Google Scholar
• Wilens T E, Prince J B, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003; 54: 9–16
   PubMed Web of Science ®Google Scholar
• Fankhauser M P, Karumanchi V C, German M L, Yates A, Karumanchi S D. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53: 77–82
   PubMed Web of Science ®Google Scholar
• Jaselskis C A, Cook E H, Jr., Fletcher K E, Leventhal B L. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992; 12: 322–7
   PubMed Web of Science ®Google Scholar
• Posey D J, Puntney J I, Sasher T M, Kem D L, McDougle C J. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004; 14: 233–41
   PubMed Web of Science ®Google Scholar
• Scahill L, Aman M G, McDougle C J, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16: 589–98
   PubMed Web of Science ®Google Scholar
• Doyle R L, Frazier J, Spencer T J, Geller D, Biederman J, Wilens T. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord 2006; 9: 543–9
   PubMedGoogle Scholar
• Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol 2006; 16: 621–9
   PubMed Web of Science ®Google Scholar
• Owley T, Salt J, Guter S, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16: 517–24
   PubMed Web of Science ®Google Scholar
• Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005; 162: 1361–9
   PubMed Web of Science ®Google Scholar
• Campbell M, Anderson L T, Small A M, Perry R, Green W H, Caplan R. The effects of haloperidol on learning and behavior in autistic children. J Autism Dev Disord 1982; 12: 167–75
   PubMed Web of Science ®Google Scholar
• Joshi P T, Capozzoli J A, Coyle J T. Low-dose neuroleptic therapy for children with childhood-onset pervasive developmental disorder. Am J Psychiatry 1988; 145: 335–8
   PubMed Web of Science ®Google Scholar
• Anderson L T, Campbell M, Adams P, Small A M, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989; 19: 227–39
   PubMed Web of Science ®Google Scholar
• Anderson L T, Campbell M, Grega D M, Perry R, Small A M, Green W H. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141: 1195–202
   PubMed Web of Science ®Google Scholar
• Ernst M, Magee H J, Gonzalez N M, Locascio J J, Rosenberg C R, Campbell M. Pimozide in autistic children. Psychopharmacol Bull 1992; 28: 187–91
   PubMedGoogle Scholar
• Campbell M, Armenteros J L, Malone R P, Adams P B, Eisenberg Z W, Overall J E. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36: 835–43
   PubMed Web of Science ®Google Scholar
• Chen N C, Bedair H S, McKay B, Bowers M B, Jr., Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 2001; 62: 479–80
   PubMed Web of Science ®Google Scholar
• Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci 2001; 26: 340–1
   PubMed Web of Science ®Google Scholar
• Zuddas A, Ledda M G, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996; 153: 738
   PubMed Web of Science ®Google Scholar
• Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol 2002; 1: 352–8
   PubMed Web of Science ®Google Scholar
• McCracken J T, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314–21
   PubMed Web of Science ®Google Scholar
• McDougle C J, Scahill L, Aman M G, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162: 1142–8
   PubMed Web of Science ®Google Scholar
• Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: e634–41
   PubMed Web of Science ®Google Scholar
• Troost P W, Lahuis B E, Steenhuis M P, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005; 44: 1137–44
   PubMed Web of Science ®Google Scholar
• Luby J, Mrakotsky C, Stalets M M, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16: 575–87
   PubMed Web of Science ®Google Scholar
• McDougle C J, Holmes J P, Carlson D C, Pelton G H, Cohen D J, Price L H. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55: 633–41
   PubMed Web of Science ®Google Scholar
• Hollander E, Wasserman S, Swanson E N, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16: 541–8
   PubMed Web of Science ®Google Scholar
• Kemner C, Willemsen-Swinkels S H, de Jonge M, Tuynman-Qua H, van Engeland H. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002; 22: 455–60
   PubMed Web of Science ®Google Scholar
• Malek-Ahmadi P, Simonds J F. Olanzapine for autistic disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1998; 37: 902
   PubMed Web of Science ®Google Scholar
• Malone R P, Cater J, Sheikh R M, Choudhury M S, Delaney M A. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40: 887–94
   PubMed Web of Science ®Google Scholar
• Potenza M N, Holmes J P, Kanes S J, McDougle C J. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999; 19: 37–44
   PubMed Web of Science ®Google Scholar
• Findling R L, McNamara N K, Gracious B L, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004; 14: 287–94
   PubMed Web of Science ®Google Scholar
• Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9: 99–107
   PubMed Web of Science ®Google Scholar
• Corson A H, Barkenbus J E, Posey D J, Stigler K A, McDougle C J. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004; 65: 1531–6
   PubMed Web of Science ®Google Scholar
• Hardan A Y, Jou R J, Handen B L. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 2005; 35: 387–91
   PubMed Web of Science ®Google Scholar
• Cohen S A, Fitzgerald B J, Khan S R, Khan A. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 2004; 65: 110–3
   PubMed Web of Science ®Google Scholar
• Goforth H W, Rao M S. Improvement in behaviour and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatry 2003; 37: 775–6
   PubMed Web of Science ®Google Scholar
• McDougle C J, Kem D L, Posey D J. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41: 921–7
   PubMed Web of Science ®Google Scholar
• Stigler K A, Posey D J, McDougle C J. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14: 455–63
   PubMed Web of Science ®Google Scholar
• Valicenti-McDermott M R, Demb H. Clinical effects and adverse reactions of off-label use of ariprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006; 16: 549–60
   PubMed Web of Science ®Google Scholar
• Hardan A Y, Jou R J, Handen B L. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14: 426–32
   PubMed Web of Science ®Google Scholar
• Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006; 9: 209–13
   PubMed Web of Science ®Google Scholar
• Ratey J J, Bemporad J, Sorgi P, et al. Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. J Autism Dev Disord 1987; 17: 439–46
   PubMed Web of Science ®Google Scholar
• McCormick L H. Treatment with buspirone in a patient with autism. Arch Fam Med 1997; 6: 368–70
   PubMedGoogle Scholar
• Realmuto G M, August G J, Garfinkel B D. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 1989; 9: 122–5
   PubMed Web of Science ®Google Scholar
• Buitelaar J K, van der Gaag R J, van der Hoeven J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry 1998; 59: 56–9
   PubMed Web of Science ®Google Scholar
• Malone R P, Gratz S S, Delaney M A, Hyman S B. Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders. CNS Drugs 2005; 19: 923–34
   PubMed Web of Science ®Google Scholar
• Geller D A, Hoog S L, Heiligenstein J H, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 773–9
   PubMed Web of Science ®Google Scholar
• Riddle M A, Scahill L, King R A, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 1062–9
   PubMed Web of Science ®Google Scholar
• Cook E H, Jr., Rowlett R, Jaselskis C, Leventhal B L. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31: 739–45
   PubMed Web of Science ®Google Scholar
• DeLong G R, Teague L A, McSwain Kamran M. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 1998; 40: 551–62
   PubMed Web of Science ®Google Scholar
• Fatemi S H, Realmuto G M, Khan L, Thuras P. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998; 28: 303–7
   PubMed Web of Science ®Google Scholar
• Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005; 30: 582–9
   PubMed Web of Science ®Google Scholar
• Martin A, Koenig K, Anderson G M, Scahill L. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Autism Dev Disord 2003; 33: 77–85
   PubMed Web of Science ®Google Scholar
• McDougle C J, Kresch L E, Posey D J. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 2000; 30: 427–35
   PubMed Web of Science ®Google Scholar
• Cook E H, Wagner K D, March J S, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2001; 40: 1175–81
   PubMed Web of Science ®Google Scholar
• March J S, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998; 280: 1752–6
   PubMed Web of Science ®Google Scholar
• Hellings J A, Kelley L A, Gabrielli W F, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996; 57: 333–6
   PubMed Web of Science ®Google Scholar
• McDougle C J, Brodkin E S, Naylor S T, Carlson D C, Cohen D J, Price L H. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998; 18: 62–6
   PubMed Web of Science ®Google Scholar
• Steingard R J, Zimnitzky B, DeMaso D R, Bauman M L, Bucci J P. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 1997; 7: 9–15
   PubMed Web of Science ®Google Scholar
• Geller D A, Wagner K D, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004; 43: 1387–96
   PubMed Web of Science ®Google Scholar
• Posey D I, Litwiller M, Koburn A, McDougle C J. Paroxetine in autism. J Am Acad Child Adolesc Psychiatry 1999; 38: 111–2
   PubMed Web of Science ®Google Scholar
• Snead R W, Boon F, Presberg J. Paroxetine for self-injurious behavior. J Am Acad Child Adolesc Psychiatry 1994; 33: 909–10
   PubMed Web of Science ®Google Scholar
• Davanzo P A, Belin T R, Widawski M H, King B H. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard 1998; 102: 427–37
   PubMedGoogle Scholar
• Namerow L B, Thomas P, Bostic J Q, Prince J, Monuteaux M C. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 2003; 24: 104–8
   PubMed Web of Science ®Google Scholar
• Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005; 44: 343–8
   PubMed Web of Science ®Google Scholar
• DeVeaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder—a multicenter trial. J Am Acad Child Adolesc Psychiatry 1992; 31: 45–9
   PubMed Web of Science ®Google Scholar
• Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21: 440–4
   PubMed Web of Science ®Google Scholar
• Sanchez L E, Campbell M, Small A M, Cueva J E, Armenteros J L, Adams P B. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996; 35: 537–44
   PubMed Web of Science ®Google Scholar
• Goff D C, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21–7
   PubMed Web of Science ®Google Scholar
• Posey D J, Kem D L, Swiezy N B, Sweeten T L, Wiegand R E, McDougle C J. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004; 161: 2115–7
   PubMed Web of Science ®Google Scholar
• Danfors T, von Knorring A L, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol 2005; 25: 485–9
   PubMed Web of Science ®Google Scholar
• Kerbeshian J, Burd L, Fisher W. Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J Clin Psychopharmacol 1987; 7: 401–5
   PubMed Web of Science ®Google Scholar
• Levy S E, Hyman S L. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev 2005; 11: 131–42
   PubMedGoogle Scholar
• Kolmen B K, Feldman H M, Handen B L, Janosky J E. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 1995; 34: 223–31
   PubMed Web of Science ®Google Scholar
• Willemsen-Swinkels S H, Buitelaar J K, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996; 39: 1023–31
   PubMed Web of Science ®Google Scholar
• Willemsen-Swinkels S H, Buitelaar J K, Weijnen F G, van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 1995; 58: 203–15
   PubMed Web of Science ®Google Scholar
• Feldman H M, Kolmen B K, Gonzaga A M. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 1999; 38: 587–93
   PubMed Web of Science ®Google Scholar
• Sandler A D, Sutton K A, DeWeese J, Girardi M A, Sheppard V, Bodfish J W. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 1999; 341: 1801–6
   PubMed Web of Science ®Google Scholar
• Ratliff-Schaub K, Carey T, Reeves G D, Rogers M A. Randomized controlled trial of transdermal secretin on behavior of children with autism. Autism 2005; 9: 256–65
   PubMed Web of Science ®Google Scholar
• Findling R L, Maxwell K, Scotese-Wojtila L, Huang J, Yamashita T, Wiznitzer M. High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord 1997; 27: 467–78
   PubMed Web of Science ®Google Scholar
• Bolman W M, Richmond J A. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord 1999; 29: 191–4
   PubMed Web of Science ®Google Scholar